SCHEMBL4553673

SCHEMBL4553673

CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)c1cc(-c2ccc(N)cc2)n(C(=O)O)n1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 1/20 0.33
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
RPA1 P27694 1/20 0.33
SYK P43405 1/20 0.33
NR1H2 P55055 2/20 0.32
TUBB4A P04350 1/20 0.31
TUBB P07437 1/20 0.31
TUBA3C P0DPH7 1/20 0.31
TUBA1B P68363 1/20 0.31
TUBA4A P68366 1/20 0.31
TUBB4B P68371 1/20 0.31
TUBB3 Q13509 1/20 0.31
TUBB2A Q13885 1/20 0.31
TUBB8 Q3ZCM7 1/20 0.31
TUBA3E Q6PEY2 1/20 0.31
TUBA1A Q71U36 1/20 0.31
TUBA1C Q9BQE3 1/20 0.31
TUBB6 Q9BUF5 1/20 0.31
TUBB2B Q9BVA1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3501462 0.91 NR1H2 (0.36) AAK1CA1CA2SYKNR1H2
SCHEMBL3499236 0.84 ALDH1A1 (0.38) PTGS2LTB4R
SCHEMBL3499314 0.78 MMP13 (0.37) AAK1NR1H2PTGS2
SCHEMBL3499073 0.77 POLB (0.33) SYKHTR2CSLC6A4
SCHEMBL3501150 0.75 ALDH1A1 (0.43) PTGS2LTB4R
SCHEMBL12134343 0.73 SYK (0.53) AAK1CA1CA2SYKPDPK1
SCHEMBL22978339 0.72 GPR119 (0.35)
SCHEMBL28485002 0.72 TUBB4A (0.44) CA1CA2NR1H2TUBB4ATUBB
SCHEMBL3516297 0.71 ELANE (0.35) NR1H2PDPK1HTR2CSLC6A4
SCHEMBL29190565 0.71 NR1H2 (0.34) NR1H2PDPK1HTR2CSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121619-A2 COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS AC Immune S.A. (CH) 2009-11-25 EP disclosed
WO-2008061796-A2 COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS AC IMMUNE SA (CH) 2008-05-29 WO disclosed